CliffBio
biologic

Tecvayli

teclistamab-cqyv

Loss of exclusivityOctober 2034projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →View the full company profile on CliffBio

Drug detail

Brand nameTecvayli
Active ingredientteclistamab-cqyv
Strength153MG/1.7ML (90MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2022
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tecvayli patent cliff — loss of exclusivity October 2034 | CliffBio